Abstract Details

Title Functional Language Lateralization of Semantic Variant PPA

Topic Aging and Dementia

Presentation(s) P03 - (-)

Poster/Presentation
Number 092

Objective

Background BACKGROUND: Atypical language lateralization, bilateral or right-lateralized, is more common in non-right handed individuals than right-handed individuals. svPPA is an asymmetric language neurodegenerative condition typically affecting the left side. Compared to the general population, we have described an increased rate of non-right handedness in svPPA. Previously, 2 cases of left-handed individuals with predominantly right-sided atrophy have had evidence for atypical language lateralization, one case with fMRI support - raising the possibility that disease vulnerability associates with language dominance. An alternative hypothesis would suggest that anomalous language lateralization is associated with disease vulnerability. However, there are no known reports of anomalous language lateralization in left-sided temporal disease to support this supposition.

Design/Methods DESIGN/METHODS: Magnetoencephalography (MEG) data was collected from a non-right-handed, left-sided, svPPA patient (UCSF Memory and Aging Center's research program on frontotemporal dementia) during a syllable reproduction and auditory noun-verb generation task using a 275-channel biomagnetometer (CTF).

Results RESULTS: Time-frequency MEG imaging reconstructions revealed a very strong bilateral network during stimulus encoding in the syllable reproduction task, as well as a strong bilateral change in beta (15-30Hz) oscillatory power during noun reproduction and verb production in the verb generation task. This is in contrast to both the highly left lateralized high-gamma and beta activity found in healthy controls during these tasks.

Conclusions CONCLUSIONS: This is the first description of a left temporal predominant svPPA patient who displays bilateral language lateralization. In the context of our prior findings of increased non-right-handedness in svPPA, this finding may strengthen the theory of anomalous language lateralization as a risk factor associated with development of svPPA while placing in question the alternative theory - disease directly associating with language dominance.

Authors/Disclosures
Zachary Miller, MD (UCSF Memory and Aging Center) PRESENTER	Dr. Miller has nothing to disclose.
Leighton Hinkley, PhD (UCSF- Radiology)	Dr. Hinkley has nothing to disclose.
	No disclosure on file
	No disclosure on file
	No disclosure on file
Maya L. Henry, PhD	No disclosure on file
	No disclosure on file
	No disclosure on file
Teri Schreiner, MD, MPH, FAAN (University of Colorado/ Children's Hospital of Colorado)	The institution of Dr. Schreiner has received personal compensation in the range of $500-$4,999 for serving as a Consultant for CDC. Dr. Schreiner has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. The institution of Dr. Schreiner has received research support from Roche Genentech.
Gil D. Rabinovici, MD, FAAN (UCSF Memory & Aging Center)	Dr. Rabinovici has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Eli Lilly. Dr. Rabinovici has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alector. Dr. Rabinovici has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Merck. Dr. Rabinovici has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Rabinovici has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Dr. Rabinovici has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novo Norodisk. Dr. Rabinovici has received personal compensation in the range of $500-$4,999 for serving as a Consultant for C2N. Dr. Rabinovici has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Johnson & Joihnson. Dr. Rabinovici has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Peerview. Dr. Rabinovici has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Medscape. Dr. Rabinovici has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for JAMA Neurology. Dr. Rabinovici has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for JAMA. The institution of Dr. Rabinovici has received research support from NIH. The institution of Dr. Rabinovici has received research support from American College of Radiology. The institution of Dr. Rabinovici has received research support from Alzheimer's Association. The institution of Dr. Rabinovici has received research support from Rainwater Charitable Foundation. Dr. Rabinovici has received personal compensation in the range of $500-$4,999 for serving as a Topic Chair, Course Director and teacher with AAN. Dr. Rabinovici has received personal compensation in the range of $500-$4,999 for serving as a Grant reviewer with NIH. Dr. Rabinovici has received personal compensation in the range of $500-$4,999 for serving as a Invited speaker with ANA.
Howard J. Rosen, MD (UCSF)	Dr. Rosen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eli Lilly . Dr. Rosen has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Alector. The institution of Dr. Rosen has received research support from NIH. The institution of Dr. Rosen has received research support from State of CA. Dr. Rosen has a non-compensated relationship as a Consultant with Prevail Therapeutics that is relevant to AAN interests or activities. Dr. Rosen has a non-compensated relationship as a consultant with Alchemab that is relevant to AAN interests or activities.
Bruce L. Miller, MD, FAAN (University of California, San Francisco)	Dr. Miller has nothing to disclose.
	No disclosure on file
Maria Luisa Gorno Tempini, MD, PhD (UCSF Memory and Aging Center)	The institution of Dr. Gorno Tempini has received research support from the NIH.

��ɫ��

��ɫ��